Fundraising Fox
/Companies
Sign in

Immitra Bio

Zürich, CH · Founded 2024 · 6 employees on LinkedIn · 8 known investors

Find your way into Immitra Bio

Sign up to see every warm intro you have to Immitra Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Immitra Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.

BiotechDeep TechMedical Devices

Founders & leadership

Immitra Bio was founded in 2024 by Amir Taheri and Jacob Corn.

ATAmir Taheri
Amir TaheriCo-founder and Chief Scientific Officer
JC
Jacob CornCo-founder and Scientific Advisor
JNJan Nelis
Jan NelisCo-founder and Chief Executive OfficerJan Nelis is co-founder and CEO of Immitra Bio, an ETH Zürich spin-off developing stem cell therapies for genetic blood disorders. He holds a degree in Molecular Health Science from ETH Zürich and has background in rowing and sports.

Investors · 8

OCCIDENT✓ confirmed by Immitra BioMunich

How we know: the company's own site · funding news · immitrabio.com · Not right? Tell us

another.vc✓ confirmed by Immitra BioMülheim an der Ruhr · $108K

How we know: the company's own site · funding news · immitrabio.com · Not right? Tell us

Backbone Ventures✓ confirmed by Immitra BioZürich · $330K – $440K

How we know: the company's own site · a partner's Signal profile · funding news · immitrabio.com · Not right? Tell us

Venture Kick✓ confirmed by Immitra BioSchlieren-Zürich

How we know: the company's own site · funding news · immitrabio.com · Not right? Tell us

Also in the syndicate · 3

ETH FoundationFONGITZürcher Kantonalbank

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform | EU-Startupseu-startups.com · Jul 2026Immitra Bio Secures CHF 2.4M / USD 3M in Pre-Seed Fundingimmitrabio.com · Jul 2026

Frequently asked questions

What does Immitra Bio do?
Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.
Who founded Immitra Bio?
Immitra Bio was founded by Amir Taheri, Jacob Corn in 2024.
Who are Immitra Bio's investors?
Immitra Bio's investors include Kickfund, OCCIDENT, another.vc, Backbone Ventures, Venture Kick.
Where is Immitra Bio headquartered?
Immitra Bio is headquartered in Zürich, CH.